Founders

Recent Posts

• Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
• Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
• Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
• Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
• Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million